Clinical Trial Update: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC [Phase 2]

View source ↗

Summary

Phase II trial of chiauranib in combination with capecitabine for triple-negative breast cancer was terminated. The update notes the study status but does not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Chiauranib (Chiauranib)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: TERMINATED